Relapsing Multiple Sclerosis (RMS) | Norton Healthcare

Indication: Relapsing Multiple Sclerosis (RMS)

A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing Oral SAR442168 to Oral Teriflunomide (Aubagio®) in Patients With Relapsing Forms of Multiple Sclerosis

Sub-indication: Relapsing Multiple Sclerosis (RMS)

Drug Study

Principal Investigator: Geeta Ganesh, M.D.
Norton Neuroscience Institute

Sponsor: Sanofi-Aventis

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.